RESULTS FOR : 'Alzheimers'
Showing 1 to 2 of 2 results |    
Keyword Search
Show#
Show#
Results Category/Section
Targeting diminished cerebral glucose metabolism for Alzheimer’s disease. Summer 13

As demographics of developed countries shift toward an older population, the number of cases of Alzheimer’s disease is anticipated to increase dramatically. Currently, there are no disease modifying treatments and approved drugs provide only symptomatic relief. Amyloid beta has been the primary drug target over the last several years, yet has not yielded any new drug approvals. Another feature of Alzheimer’s disease, diminished cerebral glucose metabolism, may offer new targets for drug development.

Targeting tau for Alzheimer’s disease and related neurodegenerative disorders. Fall 2012

There is no effective treatment for Alzheimer’s disease (AD) even though the prevalence of this neurodegenerative disorder and its associated costs are growing along with an ageing population. This article discusses whether tau could become a target for the development of disease modifying therapeutics for Alzheimer’s and other neurodegenerative disorders.